SCHEMBL6202492

SCHEMBL6202492

Nc1cc(NS(=O)(=O)CCl)ccc1F

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 4/20 0.42
ADRA2C P18825 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39
FFAR1 O14842 1/20 0.38
SOS1 Q07889 2/20 0.36
KMT2A Q03164 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SGK1 O00141 1/20 0.34
MET P08581 2/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
GAA P10253 1/20 0.34
SLC22A12 Q96S37 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2209213 0.85 ADRA2C (0.43) FFAR4ADRA2CADRA1AADRA1BFFAR1
SCHEMBL7068506 0.85 HPGD (0.49) FFAR4ADRA2CADRA1AADRA1BMAPT
SCHEMBL1462084 0.81 CYP3A4 (0.48)
SCHEMBL831738 0.80 FFAR4 (0.42) FFAR4ADRA2CADRA1AADRA1BKMT2A
Ammonia Solution, Strong SCHEMBL2209211 0.76 ADRA2C (0.55) FFAR4ADRA2CADRA1AADRA1BHPGD
SCHEMBL6200524 0.75 ALDH1A1 (0.54) FFAR4KMT2AMAPTSMN1; SMN2CA1
SCHEMBL2908147 0.72 CA1 (0.57) KMT2AHPGDSMN1; SMN2CA1CA2
SCHEMBL14115705 0.72 FFAR4 (0.77) FFAR4KMT2ASMN1; SMN2CA1CA2
SCHEMBL6202490 0.72 KMT2A (0.38) FFAR4KMT2ATHRBHPGDCA1
SCHEMBL10786767 0.70 KMT2A (0.49) KMT2ATP53MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0973739-B1 N-ARYLSULFONAMIDE- AND PYRROLIDINECARBOXYLIC ACID INTERMEDIATES, AND THEIR USE FOR THE PREPARATION OF HERBICIDAL 1,3-DIOXO-1H-PYRROLO[1,2-C]IMIDAZOLE DERIVATIVES DEGUSSA (DE) 2005-11-02 EP disclosed
US-6664400-B2 1-((4-halo-3-sulfonamidophenyl)aminocarbonyl),2-carboxy -pyrrolidine intermediate of given formula DEGUSSA AG (DE) 2003-12-16 US disclosed
US-20020137946-A1 N-arylsulfonamide and pyrrolidinecarboxylic acid intermediates, and their use for the preparation of herbicidal 1,3-dioxo-1h-pyrrolo[1,2-c]imidazole derivatives DEGUSSA AG (DE) 2002-09-26 US disclosed
US-6384234-B1 HALOGENATION DEGUSSA AG (DE) 2002-05-07 US disclosed
CN-1248244-A N-arylsulfonamide- and pyrrolidinecarboxylic acid intermediates, and their use for preparation of herbicidal 1,3-dioxo-1H-pyrrolo [1,2-c] imidazole derivatives DU PONT (US) 2000-03-22 CN disclosed
EP-0973739-A1 N-ARYLSULFONAMIDE- AND PYRROLIDINECARBOXYLIC ACID INTERMEDIATES, AND THEIR USE FOR THE PREPARATION OF HERBICIDAL 1,3-DIOXO-1H-PYRROLO[1,2-C]IMIDAZOLE DERIVATIVES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2000-01-26 EP disclosed
WO-1998037065-A1 N-ARYLSULFONAMIDE- AND PYRROLIDINECARBOXYLIC ACID INTERMEDIATES, AND THEIR USE FOR THE PREPARATION OF HERBICIDAL 1,3-DIOXO-1H-PYRROLO[1,2-C]IMIDAZOLE DERIVATIVES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1998-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137946-A1 N-arylsulfonamide and pyrrolidinecarboxylic acid intermediates, and their use for the preparation of herbicidal 1,3-dioxo-1h-pyrrolo[1,2-c]imidazole derivatives CBR3, CBR1, CLIC1 FFAR4 873/4885ADRA2C 1150/4885ADRA1A 2797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.